Proper nutrition is lacking in almost half of children with hemophilia in Iraq, with a significant portion of these children underweight compared to peers and a sizable number overweight, a study of pediatric patients in an Iraqi province found. The work also showed an association between low levels of parental education…

Once-daily preventive treatment with Novo Nordisk’s experimental therapy concizumab significantly reduced bleeding rates in people with both hemophilia A and B with inhibitors, according to new data from the Phase 3 explorer7 trial. In fact, bleeding rates in patients receiving concizumab in trial decreased by more than 85%. Based…

Hemophiliacs in Europe have never had so many reasons to feel hopeful about the future, thanks to significant recent scientific advances. But “vested interests, entrenched systems, and blatant, outright corruption limit access” to even basic healthcare in some Eastern European countries, says Amanda Bok, CEO of the Brussels-based European…

New preclinical data on one of Catalyst Biosciences’ lead candidate therapies — marzeptacog alfa activated (MarzAA), an engineered clotting Factor VIIa (FVIIa) given as an under-the-skin injection — support its potential to treat acute bleeds in people with hemophilia and its ability to be used safely in combination with Hemlibra…

Hemophilia A patients treated with CSL Behring’s Afstyla (recombinant factor 8 single-chain) require less factor to control bleeding compared to those taking octocog alfa, the company recently announced. The lower consumption holds both for patients using clotting factors on-demand and those who require preventive, or prophylactic treatment. CSL Behring…

It’s been almost 30 years since I first discovered the joy of pregnancy. I can still recall my excitement as I left the doctor’s office, clutching the positive test in my hand. I was eager to surprise my husband, Joe, who was teaching high school choir. I called his…

One ordinary evening, while a dear cousin and I relaxed in my living room, we delved into a profound conversation about purpose. We pondered why some people who struggle with mental health would cling to altruistic pursuits despite financial challenges they may have, especially since those challenges could create more…

My husband, Jared, is a capable person. He has a degree in business management and excelled in elementary and high school, consistently ranking at the top of his class. He’s an accomplished swimmer, an excellent cook, a decent handyman, and a wonderful dad. I’m not biased as his…

Dimension Therapeutics may soon become a wholly owned subsidiary of Regenxbio, following the terms of an agreement between the two companies. The merger agreement, if finalized, will add Dimension’s investigational drug candidates being developed to Regenxbio’s pipeline, including DTX201 for the treatment of hemophilia A. DTX201 was being developed…

Second in a series. Read part one. In part one of my interview with Chip Hailey, a 75-year-old from Tennessee, we explored what led him to pursue gene therapy for hemophilia B, his lifelong journey with the condition, his hopes for a new chapter, and the road to…